Lumos Pharma Financials
| LUMO Stock | USD 2.54 0.09 3.42% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 7.86 | 5.6949 |
|
|
The financial analysis of Lumos Pharma is a critical element in measuring its lifeblood. The essential information of the day-to-day investment outlook for Lumos Pharma includes many different criteria found on its balance sheet. For example, investors should never minimize Lumos Pharma's ability to pay suppliers or employees on time, making sure interest payments are not accumulating or correctly timing where and how to re-invest extra cash. Any individual investor needs to monitor Lumos Pharma's cash flow, debt, and profitability to effectively and accurately make more informed decisions on whether to invest in Lumos Pharma.
Net Income |
|
With this module, you can analyze Lumos financials for your investing period. You should be able to track the changes in Lumos Pharma individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
Lumos | Select Account or Indicator |
Understanding current and past Lumos Pharma Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Lumos Pharma's financial statements are interrelated, with each one affecting the others. For example, an increase in Lumos Pharma's assets may result in an increase in income on the income statement.
The data published in Lumos Pharma's official financial statements usually reflect Lumos Pharma's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Lumos Pharma. For example, before you start analyzing numbers published by Lumos accountants, it's critical to develop an understanding of what Lumos Pharma's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Lumos Pharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Lumos Pharma's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Lumos Pharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Lumos Pharma. Please utilize our Beneish M Score to check the likelihood of Lumos Pharma's management manipulating its earnings.
Lumos Pharma Stock Summary
Lumos Pharma competes with Pfizer, Nayax, HP, and GCM Grosvenor. Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. Lumos Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 32 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US55028X1090 |
| CUSIP | 651511107 55028X109 |
| Location | Texas; U.S.A |
| Business Address | 4200 Marathon Boulevard, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | NYSE Composite |
| Website | lumos-pharma.com |
| Phone | 512 215 2630 |
| Currency | USD - US Dollar |
You should never invest in Lumos Pharma without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Lumos Stock, because this is throwing your money away. Analyzing the key information contained in Lumos Pharma's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Lumos Pharma Key Financial Ratios
Generally speaking, Lumos Pharma's financial ratios allow both analysts and investors to convert raw data from Lumos Pharma's financial statements into concise, actionable information that can be used to evaluate the performance of Lumos Pharma over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Lumos Pharma reports annually and quarterly.| Return On Equity | -0.78 | ||||
| Operating Margin | (12.11) % | ||||
| Price To Sales | 10.44 X |
Lumos Pharma Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 96.8M | 129.0M | 100.3M | 72.3M | 40.6M | 38.6M | |
| Other Current Liab | 10.2M | 5.9M | 4.2M | 6.2M | 5.9M | 5.9M | |
| Net Debt | (89.3M) | (98.4M) | (94.3M) | (55.8M) | (28.5M) | (29.9M) | |
| Retained Earnings | (334.0M) | (66.0M) | (96.4M) | (127.5M) | (161.5M) | (169.6M) | |
| Accounts Payable | 475K | 244K | 612K | 275K | 890K | 845.5K | |
| Cash | 90.5M | 98.7M | 94.8M | 56.0M | 35.1M | 33.3M | |
| Net Receivables | 824K | 26.3M | 128K | 223K | 210K | 199.5K | |
| Other Current Assets | 3.0M | 3.5M | 4.7M | 4.4M | 3.7M | 6.2M | |
| Total Liab | 17.9M | 12.5M | 11.3M | 12.7M | 13.3M | 21.4M | |
| Total Current Assets | 94.4M | 128.4M | 99.7M | 72.0M | 40.0M | 38.0M | |
| Short Term Debt | 1.1M | 319K | 352K | 233K | 282K | 519.9K | |
| Common Stock | 373K | 374K | 83K | 82K | 81K | 77.0K | |
| Net Tangible Assets | 78.9M | 116.6M | 89.0M | 59.6M | 68.5M | 104.9M | |
| Capital Surpluse | 389.8M | 407.2M | 414.0M | 182.5M | 209.9M | 293.4M |
Lumos Pharma Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket. The other reason investors look at the income statement is to determine what Lumos Pharma's earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 50K | 7.3M | 484K | 874K | 1.0M | 671.3K | |
| Total Revenue | 936K | 168K | 230K | 1.5M | 2.1M | 1.9M | |
| Gross Profit | 899K | 168K | 230K | 1.5M | 2.0M | 1.9M | |
| Operating Income | (45.1M) | (26.3M) | (31.3M) | (32.0M) | (36.6M) | (38.4M) | |
| Ebit | (45.1M) | (26.3M) | (31.3M) | (32.0M) | (36.6M) | (38.4M) | |
| Research Development | 22.2M | 9.2M | 16.2M | 17.9M | 22.1M | 33.1M | |
| Ebitda | (42.9M) | (25.7M) | (31.1M) | (32.0M) | (36.6M) | (38.4M) | |
| Income Before Tax | (43.0M) | (19.6M) | (31.1M) | (31.1M) | (34.1M) | (35.8M) | |
| Net Income | (43.0M) | (5.7M) | (30.4M) | (31.1M) | (34.0M) | (35.7M) | |
| Income Tax Expense | 12K | (14.0M) | (636K) | (13K) | (29K) | (30.5K) | |
| Tax Provision | 12K | (14.0M) | (636K) | (13K) | (42K) | (44.1K) | |
| Interest Income | 2.2M | 200K | 12K | 874K | 2.1M | 2.2M | |
| Net Interest Income | 2.2M | 200K | 12K | 874K | 2.1M | 1.1M |
Lumos Pharma Key Cash Accounts
Cash flow analysis captures how much money flows into and out of Lumos Pharma. It measures of how well Lumos is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Lumos Pharma brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Lumos had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Lumos Pharma has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (30.2M) | 93.7M | (3.9M) | (38.8M) | (20.9M) | (19.9M) | |
| Free Cash Flow | (30.2M) | (23.0M) | (29.7M) | (26.6M) | (31.1M) | (32.6M) | |
| Depreciation | 1.1M | 584K | 203K | 49K | 44K | 41.8K | |
| Other Non Cash Items | 371K | (5.9M) | 14K | (26K) | (119K) | (113.1K) | |
| Capital Expenditures | 43K | 7K | 2K | 30K | 21K | 0.0 | |
| Net Income | (43.0M) | (5.7M) | (30.4M) | (31.1M) | (34.0M) | (35.7M) | |
| End Period Cash Flow | 90.5M | 98.7M | 94.8M | 56.0M | 35.1M | 33.3M | |
| Investments | 77K | 116.6M | 26.0M | (11.4M) | (6.8M) | (6.4M) | |
| Change Receivables | 14.4M | 10.2M | (296K) | 309K | 355.4K | 363.4K | |
| Net Borrowings | (246K) | (167K) | (61K) | (27K) | (24.3K) | (25.5K) | |
| Change To Netincome | 7.1M | (14.3M) | 2.8M | 2.3M | 2.1M | 2.0M |
Lumos Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Lumos Pharma's current stock value. Our valuation model uses many indicators to compare Lumos Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Lumos Pharma competition to find correlations between indicators driving Lumos Pharma's intrinsic value. More Info.Lumos Pharma is currently regarded as number one stock in return on equity category among related companies. It is currently regarded as number one stock in return on asset category among related companies . At this time, Lumos Pharma's Return On Equity is very stable compared to the past year.Comparative valuation analysis is a catch-all model that can be used if you cannot value Lumos Pharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Lumos Pharma's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Lumos Pharma's earnings, one of the primary drivers of an investment's value.Lumos Pharma Systematic Risk
Lumos Pharma's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Lumos Pharma volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Lumos Pharma correlated with the market. If Beta is less than 0 Lumos Pharma generally moves in the opposite direction as compared to the market. If Lumos Pharma Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Lumos Pharma is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Lumos Pharma is generally in the same direction as the market. If Beta > 1 Lumos Pharma moves generally in the same direction as, but more than the movement of the benchmark.
About Lumos Pharma Financials
What exactly are Lumos Pharma Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Lumos Pharma's income statement, its balance sheet, and the statement of cash flows. Potential Lumos Pharma investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Lumos Pharma investors may use each financial statement separately, they are all related. The changes in Lumos Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Lumos Pharma's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.Steps to analyze Lumos Pharma Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Lumos Pharma is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Lumos has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it. In summary, you can determine if Lumos Pharma's financials are consistent with your investment objective using the following steps:- Review Lumos Pharma's balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
- Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
- Study the cash flow inflows and outflows to understand Lumos Pharma's liquidity and solvency.
- Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
- Compare Lumos Pharma's financials to those of its peers to see how it stacks up and identify any potential red flags.
- Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Lumos Pharma's stock is overvalued or undervalued.
Today, most investors in Lumos Pharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Lumos Pharma's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Lumos Pharma growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Lumos Pharma May 19, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Lumos Pharma help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Lumos Pharma. We use our internally-developed statistical techniques to arrive at the intrinsic value of Lumos Pharma based on widely used predictive technical indicators. In general, we focus on analyzing Lumos Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Lumos Pharma's daily price indicators and compare them against related drivers.
| Information Ratio | (0.07) | |||
| Maximum Drawdown | 19.63 | |||
| Value At Risk | (7.20) | |||
| Potential Upside | 4.48 |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lumos Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. To learn how to invest in Lumos Stock, please use our How to Invest in Lumos Pharma guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Complementary Tools for Lumos Stock analysis
When running Lumos Pharma's price analysis, check to measure Lumos Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lumos Pharma is operating at the current time. Most of Lumos Pharma's value examination focuses on studying past and present price action to predict the probability of Lumos Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lumos Pharma's price. Additionally, you may evaluate how the addition of Lumos Pharma to your portfolios can decrease your overall portfolio volatility.
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |
Is Lumos Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lumos Pharma. If investors know Lumos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lumos Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.18) | Revenue Per Share 0.252 | Quarterly Revenue Growth 0.613 | Return On Assets (0.41) | Return On Equity (0.78) |
The market value of Lumos Pharma is measured differently than its book value, which is the value of Lumos that is recorded on the company's balance sheet. Investors also form their own opinion of Lumos Pharma's value that differs from its market value or its book value, called intrinsic value, which is Lumos Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lumos Pharma's market value can be influenced by many factors that don't directly affect Lumos Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lumos Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lumos Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lumos Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.